According to the Northeast Pharmaceutical announcement, Northeast Pharmaceutical Group Shenyang First Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the “Drug Supplement Application Approval Notice” for efavirenc tablets approved by the State Drug Administration, approved the addition of 0.2 g of the drug, and issued the drug approval number H20269225, which is valid until March 22, 2031. Effavirenc tablets are suitable for treating adults, adolescents and children infected with HIV-1 in combination with other antiviral drugs. This approval is conducive to enriching the company's product pipeline and enhancing market competitiveness.

According to the Northeast Pharmaceutical announcement, Northeast Pharmaceutical Group Shenyang First Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the “Drug Supplement Application Approval Notice” for efavirenc tablets approved by the State Drug Administration, approved the addition of 0.2 g of the drug, and issued the drug approval number H20269225, which is valid until March 22, 2031. Effavirenc tablets are suitable for treating adults, adolescents and children infected with HIV-1 in combination with other antiviral drugs. This approval is conducive to enriching the company's product pipeline and enhancing market competitiveness.